Bliss GVS Pharma Ltd updates on inspection by USFDA

Bliss GVS Pharma Limited had earlier announced that the United States Food and Drug Administration (US FDA) conducted a Pre-Approval Inspection (PAI) and Good Manufacturing Practice (GMP) at the Company's manufacturing unit at Plot No. 11, Survey No. 38/1, Dewan Udyog Nagar, Aliyali Village, Palghar, 401404, Maharashtra from Monday, March 13, 2023, to Friday, March 17, 2023.

Pursuant to above inspection by the United States Food and Drug Administration (US FDA), the Company has now received the Establishment Inspection Report (EIR) indicating closure of the inspection through which the US FDA agency assigned the inspection classification of the facility as "Voluntary Action Indicated (VAI)".

Based on this inspection and the US FDA VAI classification, this facility is in compliance with regard to current good manufacturing practices (cGMP).

Shares of Bliss GVS Pharma Limited was last trading in BSE at Rs. 79.74 as compared to the previous close of Rs. 77.08. The total number of shares traded during the day was 22669 in over 257 trades.

The stock hit an intraday high of Rs. 81.74 and intraday low of 76.66. The net turnover during the day was Rs. 1790025.00.

Source : Equity Bulls

Keywords

BlissGVSPharma INE416D01022 USFDA Inspection EIR VAI